SamaCare Launches Industry-First Prior Authorization Performance Benchmarks for Medical Benefit Drugs

Key Takeaways

• SamaCare launches industry’s first comprehensive benchmarks for medical benefit prior authorization performance across specialty practices
• New quarterly insights track approval rates and time to therapy, addressing historical lack of transparency in patient access to care
• Benchmarks derived from real-world data across tens of thousands of specialty practices using SamaCare’s platform

---

SamaCare Introduces Transparency to Prior Authorization Process

SamaCare has launched the pharmaceutical industry’s first comprehensive benchmarks for medical benefit prior authorization performance, providing unprecedented visibility into approval rates and treatment timelines across specialty practices.

The new benchmarking system analyzes real-world prior authorization activity from tens of thousands of specialty practices using SamaCare’s platform, delivering quarterly insights into approval rates and time to therapy for medical benefit drugs across various specialties and disease areas.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Addressing Critical Gap in Healthcare Transparency

While prior authorization processes play a crucial role in determining patient access to treatment, the healthcare industry has historically lacked transparency regarding how these processes impact patient care. SamaCare’s benchmarks aim to fill this critical information gap.

The platform tracks key performance indicators including approval rates, denial patterns, and the time required for patients to begin therapy after initial authorization requests. This data spans multiple therapeutic areas and specialty practices, providing a comprehensive view of prior authorization performance nationwide.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Industry Implications

The launch represents a significant step toward data-driven healthcare decision-making. Healthcare providers, payers, and pharmaceutical companies can now access standardized metrics to evaluate and improve prior authorization processes.

By providing quarterly performance insights, the benchmarks enable stakeholders to identify trends, compare performance across different therapeutic areas, and implement targeted improvements to reduce patient wait times and increase approval rates.

The initiative addresses growing concerns about prior authorization delays affecting patient outcomes and healthcare provider efficiency. With real-world data backing these benchmarks, the industry gains valuable tools for optimizing patient access to necessary medications while maintaining appropriate utilization management.

---

Frequently Asked Questions

What does this mean for patients?

Patients may experience faster access to medications as healthcare providers and payers use these benchmarks to identify and address bottlenecks in the prior authorization process.

How often will these benchmarks be updated?

SamaCare will provide quarterly updates to the benchmarks, ensuring stakeholders have access to current performance data and emerging trends.

Which therapeutic areas are covered by these benchmarks?

The benchmarks cover multiple specialties and disease areas, drawing from data across tens of thousands of specialty practices using SamaCare’s platform.

Related coverage

• Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses
• BBIA Joins EuropaBio: Strengthening the Bio-Based Economy for Pharma and Industry
• Key Cancer Drugs to Watch at ESMO 2025: Investor and BD Insights